Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities

Clinically validated mRNA platform is shown to generate differentiated products across a range of indications

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a...